| Common Brands | Caprelsa |
|---|---|
|
Drug Class |
Tyrosine kinase inhibitor |
|
Controlled Substance Classification |
Not a controlled medication |
|
Generic Status |
No Lower-cost generic available |
|
Availability |
Prescription only |
Caprelsa is an oral drug to treat medullary thyroid cancer, specifically for those that are advanced or metastatic, meaning that the cancer has spread to other parts of the body. It was designed to target and block proteins that encourage the growth of cancer cells. Caprelsa is indicated for unresectable or metastatic medullary thyroid cancer in adults.
In 2011, the FDA approved Caprelsa from clinical trials that established that it would help retard the progression of MTC. It is not considered curative but rather helps control the disease, thereby helping the patient in improving his or her quality of life due to reduction in tumor size and slowing of cancerous growth.
The commonly recommended dose of Caprelsa (vandetanib) is:
Starting Dose: 300 mg orally once daily, with or without food. Caprelsa should be taken at the same time every day.
Dose Adjustments: The dose may be adjusted based on the patient’s response and side effects. The dose may need to be reduced or interrupted if the side effects are severe.
Important Information:
Swallow the tablets whole; do not crush, break, or chew.
Side effects need to be monitored regularly, especially QT prolongation (a heart rhythm abnormality), liver function, and blood pressure.
Caprelsa is a tyrosine kinase inhibitor that works through interference with key signaling pathways that are necessary for the growth, survival, and spread of cancer cells. It works on the following mechanisms:
Inhibition of VEGFR: By inhibiting VEGFR, Caprelsa prevents the formation of new blood vessels (angiogenesis) that the tumor needs to grow and spread.
RET Gene Mutations: For medullary thyroid cancer, mutations of the RET proto-oncogene are commonly implicated in cancer development. Caprelsa blocks RET signaling, limiting cancer cell growth and metastasis in tumors harboring RET mutations.
Like all medications, Caprelsa can cause side effects, ranging from mild to severe. Common and serious side effects include:
Diarrhea: A frequent side effect, which can be managed with appropriate medications.
Rash: Skin rash may occur, often as a mild to moderate reaction.
Fatigue: Some patients experience tiredness or lack of energy while on treatment.
Nausea: A feeling of nausea or vomiting may occur, especially in the initial stages of treatment.
Loss of Appetite: Many also experience reduced levels of appetite.
Hypertension (High Blood Pressure): Some patients develop increased high blood pressure.
Severe Skin Reactions: Severe blistering or peeling of the skin can occur in some patients.
Intermittent Bleeding: Bleeding can occur, including nosebleeds or other significant bleeding events.
If any serious side effects occur, a healthcare provider should be contacted immediately.
Patients should consider the following warnings and precautions before using Caprelsa.
Risk of QT Prolongation: This drug prolongs the QT interval, leading to major heart rhythm problems. Careful monitoring should be exercised in those with a history of arrhythmias of the heart, low potassium levels, or magnesium deficiency.
Liver Function: Since Caprelsa can cause liver toxicity, the patient’s liver enzymes should be monitored on a regular basis during the treatment. Patients with diseases or dysfunction of the liver may require dose adjustments or avoid using Caprelsa.
Hypertension: Caprelsa can cause high blood pressure. The patient’s blood pressure should be monitored on a regular basis, and antihypertensive treatment may be needed for those who develop significant hypertension.
Drug Interactions: Caprelsa may interact with other drugs, particularly those that affect the liver enzymes responsible for metabolizing the drug. Patients should notify their healthcare providers of other medications, including over-the-counter drugs, they are taking.
Caprelsa (Vandetanib) is a tyrosine kinase inhibitor used primarily for treating medullary thyroid cancer. It interacts with several medications, which can affect its efficacy and safety:
Patients should have regular ECG monitoring and consult their healthcare provider before combining Caprelsa with other drugs.
The standard dose for Caprelsa is usually 300 mg once daily. Nonetheless, the dose may be modified according to the patient’s response, side effects, and other considerations
A healthcare provider may advise lowering the dose or stopping the drug in case a patient shows pronounced side effects.
Caprelsa is a prescription drug. The drug should be prescribed and taken under the guidance of a qualified healthcare provider. It should be prescribed after appropriate genetic testing to determine if patients have RET mutations, a common occurrence in medullary thyroid cancer.
Patients will have to adhere to their healthcare provider’s instructions very closely, attend regular follow-up appointments, and periodically undergo tests to monitor for side effects and treatment effectiveness.
Caprelsa is a medication used to treat certain types of medullary thyroid cancer (MTC) that cannot be surgically removed or has spread to other parts of the body.
Caprelsa is a tyrosine kinase inhibitor that works by blocking specific proteins involved in the growth and spread of cancer cells.
Caprelsa is approved for the treatment of medullary thyroid carcinoma (MTC) in adult patients.
Caprelsa is taken orally in tablet form, usually once daily, with or without food.
Common side effects may include diarrhea, nausea, vomiting, fatigue, hypertension, and rash.
Serious side effects can include severe skin reactions, liver problems, lung disease (interstitial lung disease), and heart-related issues.
The duration of treatment with Caprelsa depends on individual response to therapy and the presence of side effects; your oncologist will determine the appropriate length of treatment.
Caprelsa should not be used in patients with a known hypersensitivity to vandetanib or any of its components.
The safety and efficacy of Caprelsa in children have not been established, and it is typically not approved for pediatric use.
Patients using Caprelsa should have regular monitoring of blood pressure, liver function tests, and cardiac function.
Caprelsa is not recommended for use during pregnancy or breastfeeding due to potential harm to the fetus or infant.
Caprelsa should be stored at room temperature, away from moisture and light, and out of reach of children.
No, Caprelsa is not classified as a controlled substance.
If you miss a dose, take it as soon as you remember unless it’s close to the time of your next dose. Do not double the dose.
Caprelsa can interact with other medications, particularly those that affect liver enzymes. Always inform your healthcare provider about all medications and supplements you are taking.
Contact your healthcare provider if you experience any severe or persistent side effects, as they may need to adjust your treatment or monitor your condition more closely.
Signs of liver problems can include jaundice (yellowing of the skin or eyes), dark urine, severe abdominal pain, or unusual fatigue.
It is generally advised to limit or avoid alcohol consumption while taking Caprelsa, as it may increase the risk of certain side effects.
Caprelsa is available by prescription only, and can be obtained through specialty pharmacies or healthcare facilities.
Yes, there may be patient assistance programs available to help with the cost of Caprelsa. Patients should inquire with their healthcare provider or the manufacturer for options.
Seborrheic dermatitis is a widespread chronic inflammatory skin disorder that primarily affects the head, scalp, and upper trunk, which are areas rich in sebaceous glands.
For a considerable time, both scientists and medical experts have been fascinated by the connection between the gastrointestinal tract and the brain. The gut-brain axis
Food intolerances are becoming more widely acknowledged as serious health issues impacting people all over the world. In contrast to food allergies, which are immune
